Modulation of Epstein-Barr virus-induced B-cell activation by concanavalin A.
Direct addition of the T-cell mitogen, concanavalin A (Con A), to cultures of Epstein-Barr virus (EBV)-stimulated peripheral blood mononuclear cells (PBMC) resulted in a dose-dependent inhibition of immunoglobulin M (IgM) secreted in the supernatant, as measured by an enzyme-linked immunosorbent assay. Furthermore, Con A inhibited IgM secretion of isolated T-depleted cells stimulated with EBV, and both the proliferation and IgM secretion of EBV-driven lymphoblastoid cell lines. T-Enriched cells, precultured for 48 hr with Con A, were also able to suppress the IgM response of fresh autologous PBMC stimulated with EBV. This suppression was radiation sensitive (2000 rad), a procedure which resulted in enhancement of the IgM secretion of the responder cells in two out of three experiments. Studies on the long-term effects of Con A showed that the early suppression of IgM secretion was transient and that the mitogen prevented the development of the cytotoxic T-cell response normally seen with lymphocytes from EBV-seropositive donors after 5 weeks of culture. Thus, Con A appears to modulate human lymphocyte responses to EBV by multiple mechanisms.
D001402:B-Lymphocytes / Q000276:immunology*; D002453:Cell Cycle / Q000187:drug effects; D003208:Concanavalin A / Q000494:pharmacology*; D004854:Herpesvirus 4, Human / Q000276:immunology*; D007075:Immunoglobulin M / Q000096:biosynthesis*; D008213:Lymphocyte Activation; D013601:T-Lymphocytes / Q000276:immunology
D007075:Immunoglobulin M; D003208:Concanavalin A